BENGALURU: Pharmaceutical drugmaker Dr. Reddy’s Laboratories Ltd released a preliminary schedule for Indian trials of Russia’s coronavirus vaccine candidate on Wednesday, with the final stage expected to be completed in March 2021.
Israeli Executive Director Erez said enrollment for the Sputnik-V vaccine mid-stage trial will begin in the coming weeks and the trial is likely to end in December.
“(The Phase 3 test) may end as quickly as the end of March, but it could go into April or May,” Israel told a post-earnings press conference, adding that the timeline will depend on the results of the Phase 2 testing and more. Authorities approvals.
With 8 million Covid-19 infections and second only to the United States, India is pinning its hopes on a vaccine to stop the spread of the pandemic.
Healthcare experts see the ongoing holiday season and state assembly elections adding to the challenges in containing the outbreak.
The Hyderabad-based company had received renewed approval for India’s late-stage clinical trials of the Sputnik-V vaccine earlier this month, after initially signing an agreement with Russia’s Direct Investment Fund in September.
The company expects to register 100 participants for the intermediate stage test and 1,500 people for the late stage.
The drugmaker, which last week isolated all its data center services as a preventative measure following a cyber attack, said it was a ransomware attack, but it had not yet been determined whether any personal information had been accessed.
Israeli Executive Director Erez said enrollment for the Sputnik-V vaccine mid-stage trial will begin in the coming weeks and the trial is likely to end in December.
“(The Phase 3 test) may end as quickly as the end of March, but it could go into April or May,” Israel told a post-earnings press conference, adding that the timeline will depend on the results of the Phase 2 testing and more. Authorities approvals.
With 8 million Covid-19 infections and second only to the United States, India is pinning its hopes on a vaccine to stop the spread of the pandemic.
Healthcare experts see the ongoing holiday season and state assembly elections adding to the challenges in containing the outbreak.
The Hyderabad-based company had received renewed approval for India’s late-stage clinical trials of the Sputnik-V vaccine earlier this month, after initially signing an agreement with Russia’s Direct Investment Fund in September.
The company expects to register 100 participants for the intermediate stage test and 1,500 people for the late stage.
The drugmaker, which last week isolated all its data center services as a preventative measure following a cyber attack, said it was a ransomware attack, but it had not yet been determined whether any personal information had been accessed.
.
